What is Immuneering?
Immuneering is a clinical-stage biotechnology firm dedicated to the development and commercialization of universal-RAS/RAF medicines. The company's core innovation lies in its Deep Cyclic Inhibition of the MAPK pathway, a mechanism designed to achieve high efficacy against cancer cells while minimizing toxicity to healthy tissue. Its lead candidate, IMM-1-104, is currently undergoing Phase 1/2a trials for patients with advanced solid tumors harboring RAS mutations, while IMM-6-415 targets similar mutations in both RAS and RAF. By focusing on these high-unmet-need patient populations, Immuneering occupies a specialized niche in the oncology sector, bridging the gap between fundamental scientific research and actionable clinical solutions.
How much funding has Immuneering raised?
Immuneering has raised a total of $219.5M across 4 funding rounds:
Series A
$20M
Series B
$62M
Share Placement
$112.5M
Stock/Share Issuance
$25M
Series A (2020): $20M with participation from Boxcar PMJ LLC
Series B (2021): $62M led by LYFE Capital, Surveyor Capital, T. Rowe Price, Perceptive Advisors, BlackRock, Rock Springs Capital, and Cormorant Asset Management
Share Placement (2021): $112.5M, investors not publicly disclosed
Stock/Share Issuance (2025): $25M, investors not publicly disclosed
Key Investors in Immuneering
T. Rowe Price
A global asset management organization providing comprehensive investment solutions and financial services, known for its active management and fundamental research approach.
Perceptive Advisors
A New York-based investment firm managing significant assets with a specialized focus on funding innovative healthcare and life sciences technologies.
BlackRock
One of the world's largest investment management firms, offering a diverse range of products and services across multiple asset classes and global markets.
What's next for Immuneering?
Looking ahead, Immuneering is poised to leverage its recent capital influx to expedite the clinical validation of its primary assets. The strategic focus will likely remain on the successful execution of ongoing Phase 1/2a trials, with an emphasis on data readout quality and regulatory milestones. As the company matures, the integration of its early-stage programs into the broader development pipeline will be critical for long-term value creation. Investors will be closely monitoring the efficacy signals from IMM-1-104 and IMM-6-415, as these results will serve as the primary catalysts for future valuation growth and potential strategic partnerships within the global biopharmaceutical ecosystem.
See full Immuneering company page
